E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer
Gabriella C. Russo,Ashleigh J. Crawford,David Clark,Julie Cui,Ryan Carney,Michelle N. Karl,Boyang Su,Bartholomew Starich,Tung-Shing Lih,Pratik Kamat,Qiming Zhang,Praful R. Nair,Pei-Hsun Wu,Meng-Horng Lee,Hon S. Leong,Hui Zhang,Vito W. Rebecca,Denis Wirtz
DOI: https://doi.org/10.1038/s41388-024-03007-2
IF: 8.756
2024-03-20
Oncogene
Abstract:The loss of intercellular adhesion molecule E-cadherin is a hallmark of the epithelial-mesenchymal transition (EMT), during which tumor cells transition into an invasive phenotype. Accordingly, E-cadherin has long been considered a tumor suppressor gene; however, E-cadherin expression is paradoxically correlated with breast cancer survival rates. Using novel multi-compartment organoids and multiple in vivo models, we show that E-cadherin promotes a hyper-proliferative phenotype in breast cancer cells via interaction with the transmembrane receptor EGFR. The E-cad and EGFR interaction results in activation of the MEK/ERK signaling pathway, leading to a significant increase in proliferation via activation of transcription factors, including c-Fos . Pharmacological inhibition of MEK activity in E-cadherin positive breast cancer significantly decreases both tumor growth and macro-metastasis in vivo. This work provides evidence for a novel role of E-cadherin in breast tumor progression and identifies a new target to treat hyper-proliferative E-cadherin-positive breast tumors, thus providing the foundation to utilize E-cadherin as a biomarker for specific therapeutic success.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology